06-reference/research

patient data rights startups 2024 2026 scan

2026-07-09·research-brief·source: deep-research
competitor-scanpatient-data-sovereigntynovelliahealth-data-consentblind-spot-sweep

2024-2026 Patient-Data-Rights Startups — Residual Blind-Spot Sweep (No New 3/3)

The question

"2024-2026 patient-data-rights startups not on the May 11 radar — Crunchbase-style scan for companies founded 2024-2026 in category 'patient data' / 'health data sovereignty' / 'consent platform'. Close residual blind spots in the competitor scan." Context: RDCO's active patient-data-sovereignty competitor-tracking thread; the task flagged CIQ, Mira, TrustLayer and "others" as names possibly never searched, and asked to score any newcomer against the 3-leg (Data Sovereignty + Value-Based Care + Patient Incentive) rubric.

What we already know (from the vault)

What the web says

Convergences and contradictions

Synthesis for RDCO

The white-space verdict from May 11 holds and is arguably reinforced. The one real addition to the competitive map, Novellia, is a well-funded ($18M Series A, June 2026) but structurally familiar entrant: a free-to-patient personal-health-records vault monetized by selling de-identified aggregated data to pharma for real-world evidence. That is the PicnicHealth/ThumbPrint model, re-run by a fresh team with fresh capital. It scores 1/3 on the rubric — patient-anchored data (DS partial), no payer downside-risk contract (VBC no), and — the load-bearing point — explicitly no patient cash ("completely free… funded through partnerships"). Patients are the data source, not the economic beneficiary. The wedge (patient as structural data principal AND in the savings split AND inside a VBC) remains uncontested.

The more useful strategic read is a pattern, not a single name. Across two months, the three closest incumbents (PicnicHealth, Embleema, Health Wizz) drifted away from the wedge toward pharma RWE, yet a fresh $18M round just funded a new company to occupy the exact spot they left. The RWE-data-broker gravity well is real and well-capitalized; the value-based-care + patient-payout combination is the part venture keeps not funding. That asymmetry is the moat signal: the DS leg is a crowded, fundable, commoditizing UX layer, while the VBC+PI economics remain the genuinely hard, uncrowded half. RDCO's differentiation statement should lean even harder on the economics legs and treat "patient-anchored PHR" as table stakes a new competitor can buy for ~$18M, not as the moat.

Net effect on the map: no re-rank of the bet-architecture variants, no kill signal, no acceleration change. Add Novellia to the 1/3 row alongside PicnicHealth/Seqster; keep watching it for the one move that would matter — a partnership announcement with a VBC operator (Aledade/Strive/Evolent-shape), which would push it toward 2/3 fast, exactly the trigger flagged for PicnicHealth in the May 11 follow-ups.

Confidence: moderate. Crunchbase itself is login-gated and was not directly queried; findings rest on public web coverage (Fierce funding tracker, newmarketpitch analysis, company sites) and prior web-search snippets. Novellia's founding year is inferred (copyright 2025), not confirmed. Investor list is from a secondary search snippet, not a primary release. Treat funding facts as directionally reliable, exact founding dates as unconfirmed.

Open follow-ups

Related

Sources

Vault:

Web (accessed 2026-07-09):